Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia
- 1 May 2009
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (3) , 194-200
- https://doi.org/10.2353/jmoldx.2009.080047
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic LeukemiaThe Journal of Molecular Diagnostics, 2009
- Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaLeukemia, 2008
- Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Blood, 2007
- Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subcloneBlood, 2007
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingLeukemia, 2007
- Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemiaBest Practice & Research Clinical Haematology, 2002
- Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapyLeukemia, 2001
- Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemiaLeukemia, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998